Streetbeat News

Stock Prices

RILY

B. Riley Financial shares rose by 11.1% after announcing strategic initiatives, including selling a majority stake in Great American Group and securing $236 million in debt financing. These moves aim to generate $410 million in cash to reduce senior secured debt to $125 million by 2024.

Portfolio Pulse from Vaishali Prayag

September 09, 2024 | 6:13 pm

AAPL

Apple has announced the new iPhone 16 priced at $799 and iPhone 16 Plus at $899, potentially impacting its stock price.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:12 pm

BA

GCAD

ITA

Boeing's shares rise following a tentative union deal to prevent a strike and the successful return of the Starliner. The deal includes a 25% wage increase and a commitment to build the next commercial airplane in Seattle. Analyst Ronald J. Epstein remains neutral pending the union vote.

Portfolio Pulse from Lekha Gupta

September 09, 2024 | 6:11 pm

MGNX

MacroGenics shares rise as the company announces it will present Phase 2 results from its TAMARACK trial on innovative cancer treatment at ESMO 2024.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:09 pm

EYEN

Eyenovia's stock is rising following the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharma.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:06 pm

AZN

ELVN

PFE

HC Wainwright initiated coverage on Enliven Therapeutics (NASDAQ:ELVN), highlighting its promising leukemia candidate ELVN-001, which could challenge existing treatments from Pfizer and AstraZeneca. The analyst gave a Buy rating with a $37 price target, noting potential peak sales of over $500 million.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 6:05 pm

AZN

AstraZeneca PLC shares declined after the company reported that its drug, Datopotamab deruxtecan, failed to achieve statistical significance and did not show an improvement in overall survival.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:03 pm

JAZZ

Analysts have mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ), with recent evaluations showing a decrease in the average 12-month price target from $170 to $164.5. The company's financials reveal a strong net margin and ROA, but challenges in ROE and revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm

ARVN

Arvinas (NASDAQ:ARVN) has been analyzed by four analysts, showing a range of ratings from bullish to bearish. The average 12-month price target has decreased by 11.68% to $60.5. Analysts have maintained or lowered their ratings, reflecting a negative shift in sentiment. Despite a positive revenue growth rate of 40.37%, Arvinas faces challenges with net margin, ROE, and ROA below industry benchmarks.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) has been analyzed by five analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $38.8, a decrease from the previous $43.40. The company faces financial challenges, including a significant revenue decline and negative net margin, but has a strong ROE and ROA. Analysts maintain varied ratings, with some lowering their price targets.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 6:01 pm